A proven effective therapy for the treatment of RRMM
When MM progresses, make XPOVIO® your patient’s next step
A proven effective therapy for the treatment of RRMM
When MM progresses, make XPOVIO® your patient’s next step
XPOVIO® (selinexor) is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.1 For full prescribing details, please visit: www.xpoviopm.ca
XPOVIO® in combination with bortezomib and dexamethasone demonstrated a statistically significant improvement in progression-free survival versus bortezomib and dexamethasone alone1,2*
Median progression-free survival
(HR: 0.70, 95% CI: 0.53–0.93; p=0.0075)
13.93 months
XPOVIO® in combination with
bortezomib and dexamethasone
vs.
9.46 months
Bortezomib and
dexamethasone alone
CI, confidence interval; HR, hazard ratio; MM, multiple myeloma; RRMM, relapsed refractory multiple myeloma.
* The BOSTON trial was a Phase 3, global, randomized, open-label study that evaluated the clinical benefit of once-weekly XPOVIO® in combination with once-weekly bortezomib and twice-weekly dexamethasone (n=195) versus twice-weekly bortezomib and four-times-weekly dexamethasone alone (n=207) in patients with multiple myeloma who have received 1-3 prior therapies.
References
1. FORUS Therapeutics Inc. XPOVIO® (selinexor tablets) Product Monograph. March 22, 2024.
2. Grosicki S, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563-1573.